Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 87.62
Bid: 93.35
Ask: 93.36
Change: 0.35 (0.401%)
Spread: 0.01 (0.011%)
Open: 87.64
High: 88.78
Low: 87.14
Prev. Close: 88.11
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Drugs group Sanofi makes Olympic jump in rebrand bid

Wed, 10th Jan 2024 06:00

LONDON, Jan 10 (Reuters) - Sanofi is hoping that by sponsoring the Olympic Games it can attract new talent, reward existing staff and shake off the French drugmaker's conservative image.

The 2024 Games has gained other new partners from the host nation France, including luxury goods giant LVMH and supermarket group Carrefour.

Sanofi, which some estimate is spending tens of millions of euros on the Paris Games, says it has sometimes struggled to convince prospective young data managers and data scientists that a pharmaceuticals company is a "cool" place to work.

"We're using the Olympics to show that we are," said Josep Catlla, head of corporate affairs at Sanofi, which is also supporting popular French breakdancer Dany Dann.

The median age of Olympics viewers is rising, data firms have said, and the International Olympic Committee has been trying to drum up Gen Z and Millennial interest through social media campaigns as younger audiences move away from TV, and by introducing newer sports such as breakdancing and skateboarding.

Sanofi is financially supporting 14 individuals in Paris, including British Paralympic swimmer Ellie Challis, in a team comprising an equal number of men and women, and an equal number of Olympic and Paralympic athletes.

"We're playing into the diversity aspect," Catlla said.

Sanofi is also bringing more than 8,000 employees to the Games as volunteers or through internal rewards programmes.

It declined to give details of how much it is spending, saying it is "putting as much money back into our employees as we have paid to the games organizer".

Olympic sponsorship fees alone are between 80 million euros ($87.5 million) and 150 million euros, French media reports have said.

Nick Blenkarne, head of strategy at branding agency Imagination in London, said Sanofi is likely to be looking at its "expensive" sponsorship through several lenses.

These include how it could change the way consumers perceive the company, how it could attract business customers through hospitality programmes, and how it could widen its appeal.

"Positioning yourself as an organisation that wants to do good in the world is always going to be good for attracting new talent," said Blenkarne, whose firm has worked with Samsung and Hyundai at previous Olympic Games.

"Big events like the Olympics and the World Cup are proven to move the needle when it comes to brand perception," he added, noting that brands like Cisco and Visa have also been unlikely, but long-time, Olympic sponsors.

'EXCEPTION'

Catlla said Sanofi, which is one of the biggest makers of vaccines and anti-inflammation treatments and normally sponsors events relating to diseases or patient communities, has made an "exception" for the Olympics partly because they are in Paris.

"We're not in sport and culture or music or other things consumer goods companies do," he added.

The Olympic Games have traditionally seen one-off sponsors from host nations that are not part of the sports or consumer industries. Partners of the Tokyo 2020 Olympics included firms such as Tokyo Gas, Japan Airlines, Nomura and Tanaka Holdings.

Sanofi did not comment when asked whether the French government had suggested it sponsor the Paris Olympics

It remains to see whether Sanofi's sponsorship will move the dial for investor perceptions, after several years of mixed financial results.

"Maybe (the Olympics) is another opportunity to change minds on the company's innovation engine," said Terence McManus, a fund manager with a focus on healthcare at Switzerland's Bellevue Asset Management, which is a Sanofi shareholder.

In October, Sanofi abandoned its 2025 profit target under a plan to list its consumer healthcare business and spend more on testing innovative drugs, wiping 20 billion euros ($22 billion) off its market value.

Sanofi CEO Paul Hudson, who joined four years ago with a mandate to turn the company around, has faced setbacks including the failure of breast cancer pill amcenestrant and losing out in the race for a COVID-19 vaccine.

"I think this (the Olympics) is maybe part of a wider cultural change that the new management team has been at the head of since various members joined between 2019 and now," said Tom Lemaigre, European equities portfolio manager at Sanofi investor Janus Henderson.

"I don't know how sponsoring the Olympics can be seen as a force for bad. They're about unity and competition -- people performing at the highest level."

Lemaigre noted that to the general public and potential employees there could be "a kind of cachet", but "sponsoring a big event like this in and of itself isn't going to change an investor's perception on the company." ($1 = 0.9140 euros) (Reporting by Richa Naidu and Ludwig Berger. Additional reporting by Helen Reid; Editing by Matt Scuffham and Alexander Smith)

More News
20 Jun 2024 16:01

Industry groups back drugmakers' appeal in Zantac cancer lawsuits

June 20 (Reuters) - A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.

Read more
11 Jun 2024 00:32

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

June 10 (Reuters) -

Read more
10 Jun 2024 22:49

Latest trial over Zantac cancer claims called off as plaintiff drops case

June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced.

Read more
7 Jun 2024 19:34

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, June 7 (Reuters) - The outbreak of bird flu in U.S. dairy cows has now been confirmed in Minnesota and Iowa, bringing to 11 the total number of affected states, which have been encouraged to ramp up testing efforts at the request of government officials.

Read more
1 Jun 2024 21:35

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
1 Jun 2024 21:07

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
30 May 2024 20:56

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found in dairy cattle in nine states. This second case in a Michigan dairy worker was found through increased testing of people and cows in the state following the April 1 identification of a case in a Texas farm worker. Here's what you need to know about the outbreak.

WHY IS H5N1 OR BIRD FLU A CONCERN?

Read more
27 May 2024 06:00

US, European nations consider vaccinating workers exposed to bird flu

CHICAGO/LONDON, May 27 (Reuters) - The United States and Europe are taking steps to acquire or manufacture H5N1 bird flu vaccines that could be used to protect at-risk poultry and dairy workers, veterinarians and lab technicians, government officials said, moves influenza experts say could curb the threat of a pandemic.

Read more
23 May 2024 19:21

Zantac not a cause of woman’s cancer, jury says in first trial over drug

CHICAGO, May 23 (Reuters) - A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands of lawsuits making similar allegations.

Read more
22 May 2024 22:59

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 22 (Reuters) -

Read more
10 May 2024 17:21

STOXX 600 closes at record high on earnings, rate cut optimism

Rio Tinto considered bid for BHP-target Anglo American -report

*

Read more
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.